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Background: SHANK proteins are crucial for the formation and plasticity of excitatory synapses. Although mutations in
all three SHANK genes are associated with autism spectrum disorder (ASD), SHANK3 appears to be the major ASD gene
with a prevalence of approximately 0.5% for SHANK3 mutations in ASD, with higher rates in individuals with ASD and
intellectual disability (ID). Interestingly, the most relevant mutations are typically de novo and often are frameshift or
nonsense mutations resulting in a premature stop and a truncation of SHANK3 protein.
Methods: We analyzed three different SHANK3 stop mutations that we identified in individuals with ASD and/or ID,
one novel (c.5008A > T) and two that we recently described (c.1527G > A, c.2497delG). The mutations were inserted
into the human SHANK3a sequence and analyzed for effects on subcellular localization and neuronal morphology
when overexpressed in rat primary hippocampal neurons.
Results: Clinically, all three individuals harboring these mutations had global developmental delays and ID. In our in vitro
assay, c.1527G > A and c.2497delG both result in proteins that lack most of the SHANK3a C-terminus and accumulate in
the nucleus of transfected cells. Cells expressing these mutants exhibit converging morphological phenotypes including
reduced complexity of the dendritic tree, less spines, and less excitatory, but not inhibitory synapses. In contrast,
the truncated protein based on c.5008A > T, which lacks only a short part of the sterile alpha motif (SAM) domain
in the very SHANK3a C-terminus, does not accumulate in the nucleus and has minor effects on neuronal morphology.
Conclusions: In spite of the prevalence of SHANK3 disruptions in ASD and ID, only a few human mutations have been
functionally characterized; here we characterize three additional mutations. Considering the transcriptional and functional
complexity of SHANK3 in healthy neurons, we propose that any heterozygous stop mutation in SHANK3 will lead to a
dysequilibrium of SHANK3 isoform expression and alterations in the stoichiometry of SHANK3 protein complexes,
resulting in a distinct perturbation of neuronal morphology. This could explain why the clinical phenotype in all
three individuals included in this study remains quite severe - regardless of whether there are disruptions in one
or more SHANK3 interaction domains.
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Autism spectrum disorder (ASD) is a neuropsychiatric
condition manifesting in early development and is charac-
terized by two core features: A) persistent deficits in social
interaction and communication and B) the presence of
restricted interests and/or repetitive behaviors [1]. The
strong involvement of genetics in the development of ASD
is supported by the identification of causative genetic ab-
normalities in more than 20% of cases, with a significant
number of the identified genes encoding proteins required
for the correct formation, maturation, and maintenance of
synaptic connections in the brain [2-9]. Among these, the
SHANK gene family plays a decisive role because diverse
genetic variation in SHANK1, SHANK2, and SHANK3 - all
encoding large postsynaptic scaffold proteins - has been
identified in individuals with ASD [10-16]. A crucial role of
SHANK3 mutations in this context is supported by the
following three facts: 1) SHANK3 haploinsufficiency is
the critical factor for the development of neuropsychiatric
symptoms in 22q13 deletion syndrome, also known as
Phelan-McDermid syndrome, 2) the current prevalence
for SHANK3 mutations in individuals with ASD in general
is between 0.5% and 0.7%, and 3) data indicate that a
SHANK3 mutation is present in approximately 2% of
individuals with both ASD and intellectual disability
(ID) [16-18].
Some individuals diagnosed with either ASD, ID, or
both harbor frameshift or nonsense mutations in
SHANK3 resulting in a premature stop codon and caus-
ing a truncation of SHANK3 protein [15-17,19-22].
However, only a few studies have thus far addressed the
impact of such mutations and their corresponding trun-
cated proteins on neuronal function and morphology
[15,19,22-25]. In this context, the de novo exon 21
frameshift mutation c.3679_3680insG - identified in two
brothers diagnosed with both ASD and ID [15] - and the de
novo exon 21 nonsense mutation c.3349C >T - identified
in three brothers, all of them diagnosed with ID, with two
having an additional diagnosis of schizophrenia (SCZ)
[19] - have been most intensely studied up to date
[15,19,23-25]. Insertion of either stop mutation into the
rat Shank3a sequence at the corresponding sites results
in the expression of truncated Shank3a variants lacking
distinct parts of the C-terminus, a region crucial for ap-
propriate synaptic targeting and assembly [26-29]. In con-
trast to wild-type Shank3a, Shank3a harboring either
c.3679_3680insG or c.3349C >T mutations no more clus-
ter at synapses, but rather distribute in the somatodendritic
compartment and localize to the nucleus when overex-
pressed in primary hippocampal neurons [15,19,23-25].
Overexpression of Shank3a harboring the c.3679_3680insG
mutation affects growth cone mobility and negatively inter-
feres with synaptic transmission and transsynaptic signal-
ing; the same mutation leads to reductions in the numberof excitatory synapses and dendritic spines [15,23,24].
Shank3a harboring the c.3349C >T mutation impairs the
ability of Shank3a to promote the outgrowth of primary
neurites, results in a less complex dendritic arbor, and leads
to a specific reduction of excitatory, but not inhibitory
synapses [19,25]. In vitro examination of a de novo exon 21
nonsense mutation c.2997C >G identified in a boy with ID
demonstrated a reduction in neurite nodes, tips, and
length, at early stages of neuronal differentiation [22].
Taken together, these in vitro studies show that trunca-
tions of the distal C-terminus of Shank3a, caused by
the c.3679_3680insG, c.3349C > T or c.2997C > G mu-
tations are sufficient to disrupt neuronal morphology
when the truncated variant is overexpressed in primary
neuronal cultures.
However, the three stop mutations studied to date all
affect exon 21 of SHANK3, but less is known about
mutations identified in ASD and/or ID that affect other
parts of the gene [15-17,19-22]. It is therefore of high
interest to evaluate additional mutations, including those
that disrupt other exons of SHANK3 and to identify con-
verging and/or distinct neuronal pathologies.
We inserted three mutations identified in subjects with
ASD and/or ID into the human SHANK3a sequence: a
nonsense mutation affecting exon 12 (c.1527G >A), a
frameshift mutation affecting exon 21 (c.2497delG) - both
recently described [17] - and one novel nonsense mutation
affecting exon 22 (c.5008A > T). Clinical assessment of the
corresponding subjects was followed by characterization
of the impact of the three truncated SHANK3a variants
with respect to subcellular localization, dendritic branch-
ing, and spine and synapse formation, when overexpressed




The Institutional Review Board (IRB) of Icahn School of
Medicine at Mount Sinai approved all studies involving
humans, and all subjects were recruited under an IRB
approved protocol as part of ongoing studies in Phelan-
McDermid syndrome at the Seaver Autism Center for
Research and Treatment at the Icahn School of Medicine
at Mount Sinai with parents providing informed consent.
An inter-disciplinary evaluation team conducted compre-
hensive assessments using the following clinical evaluation
tools: (1) Clinical genetic evaluations and dysmorphology
exams; (2) Neurological examination to evaluate gross
motor skills and gait, fine motor coordination, cranial
nerves, and deep tendon reflexes; (3) ASD focused diagnos-
tic evaluation using the Diagnostic and Statistical Manual
for Mental Disorders-IV (DSM-IV), the Autism Diagnostic
Observation Schedule-2 (ADOS-2), and the Autism Diag-
nostic Interview Revised (ADI-R); (4) Cognitive testing
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Vineland Adaptive Behavior Scales-II, Survey Edition,
to evaluate independence in daily life skills, including
communication, socialization, and motor skills; (6)
Medical record review including analyzing any results
from electroencephalographic and brain imaging stud-
ies; and (7) Genetic testing for confirming mutation and
de novo origin, using Sanger sequencing.
Vector constructs
Human SHANK3a complementary DNA (cDNA) based
on NP_277052.1 was re-designed in collaboration with
GeneArt® (Life Technologies, Carlsbad, CA, USA) for
optimized GC content, and a Myc-tag was added immedi-
ately after the initiation codon. Subcloning was performed
using In-Fusion HD (Clontech Laboratories, Mountain
View, CA, USA). The entire SHANK3a cDNA was ampli-
fied using the following set of primers: 5′-GTCCGGACTC
AGATCTATGGAGCAGAAGCTGATCAG-3′ and 5′-GT
CGACTGCAGAATTCTCAGCTGCCGTCCAGCTGT-3′,
and further inserted into the pAcGFP1-C1 (Clontech
Laboratories, Mountain View, CA, USA) vector using
Bgl2 and EcoR1 sites. The sequence was confirmed by
Sanger sequencing. The c.1527G >A variant was generated
by using the primer set 5′-GCTTCTGaGAGGGCACCGT
GAAG-3′ and 5′-TGCCCTCtCAGAAGCCGCCctcg-3′.
The c.2497delG variant was generated by inserting a frag-
ment containing the deletion followed by authentic human
SHANK3 cDNA corresponding to the sequence from
immediately after the variation to the predicated premature
termination codon. The c.5008A >T variant was generated
by using the primer set 5′-GTGGTCCtAGTTCGACGTG
GGCGACTGG-3′ and 5′-CGAACTaGGACCACAGCTG
CAGGGGTTT-3′. The eGFP-Shank3a and DenMark con-
structs have been described previously [29,30].
Antibodies
A novel polyclonal antibody directed against the rat
Shank3a N-terminus (aa 333-470) was generated for this
study according to the antibody production and purifica-
tion protocol described in [31]. The anti-Shank3 PRC
antibody has been described previously [31]. The follow-
ing primary antibodies were purchased from commercial
suppliers: anti-histone H3 (Cell Signaling Technology,
Danvers, MA, USA), anti-green fluorescent protein (GFP)
(Clontech, Laboratories, Mountain View, CA, USA), anti-c-
Myc (Roche Applied Science, Mannheim, Germany), as
well as anti-GAPDH, anti-VGLUT1, and anti-VGAT (all
from Synaptic Systems, Goettingen, Germany).
Biochemistry
For whole culture extracts, transfected HEK293T cells were
lysed in Triton X-100 Lysis Buffer (150 mM NaCl, 50 mM
Tris HCl, 1% Triton X-100, pH 8,0, protease inhibitor mix,Roche Applied Science, Mannheim, Germany). The
NE-PER Nuclear and Cytoplasmic Extraction Reagents
(Thermo Scientific, Bonn, Germany) were further used
to obtain nuclear and cytoplasmic fractions from trans-
fected HEK293T cells. Protein concentrations were deter-
mined by Bradford protein assay, and the same amount of
protein was loaded per lane for SDS-PAGE. Western blot
analysis was conducted following standard protocols.
HRP-conjugated secondary antibodies (Dako, Glostrup,
Denmark) and the SuperSignal detection system (Thermo
Scientific, Bonn, Germany) were used to visualize protein
bands on X-ray films (GE Healthcare, Freiburg, Germany).
Animal experiments
All animal experiments in this study were performed
based on the guidelines for the welfare of experimental
animals issued by the Federal Government of Germany
and by the local ethics committee (Ulm University), ID
Number: 0.103.
Cell culture
HEK293T cells were maintained in DMEM at 37°C in
5% CO2. The preparation of hippocampal cultures
from rat was performed at embryonic stage 18 (E18) as
described previously [32]. In brief, hippocampal neu-
rons were seeded on poly-l-lysine (0.1 mg/ml, Sigma-
Aldrich, Steinheim, Germany)-coated glass coverslips.
Cells were grown in neurobasal medium, complemented
with B27 supplement, 0.5 mM L-glutamine and penicillin/
streptomycin at 100 U/ml (all reagents from Life Tech-
nologies, Darmstadt, Germany), and maintained at 37°C in
5% CO2.
Immunocytochemistry
Immunocytochemistry was performed as described pre-
viously with minor modifications [33]. Cultured cells
were fixed with 4% paraformaldehyde (PFA)/1.5% su-
crose in phosphate-buffered saline (PBS) at RT for 20
min and processed for immunocytochemistry. After
permeabilization of the cells with 0.1% Triton X-100 in
PBS for 5 min, blocking was performed using 5% FCS in
PBS, followed by the primary antibody at 4°C overnight.
Washing with PBS was followed by incubation with the
secondary antibody coupled to Alexa Fluor® 488, 568, or
647 (all from Life Technologies, Darmstadt, Germany)
for 1 h at room temperature. The actin cytoskeleton
was visualized by Alexa Fluor® 647 Phalloidin in some
experiments. Cell nuclei were counterstained with 4′,6-
diamidino-2-phenylindole (DAPI), and after further
washing steps, cells were mounted in mowiol. Images
were captured using an upright fluorescence microscope
(Axioskop 2, Zeiss, Oberkochen, Germany) and Axiovision
software (Zeiss, Oberkochen, Germany).
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Vector constructs were transfected into HEK293T cells
using PolyFect reagent (Qiagen, Hilden, Germany) as de-
scribed previously [34] or into hippocampal neurons
using Lipofectamine 2000 reagent (Life Technologies,
Darmstadt, Germany).
Analysis of neuronal morphology
All analyses were done in a blinded fashion. Sholl ana-
lysis was performed as described previously [35]. Con-
centric circles (15, 30, 45, 60, 75, 90, 105, 120, 135, and
150 μm in diameter) were drawn around the soma of
each neuron included in the analysis. The number of all
dendrites crossing each circle was counted manually. For
analysis of spines and filopodia, two secondary dendrites
were randomly chosen per neuron and dendritic pro-
trusions were counted manually among approximately
35-μm-long segments per dendrite. Dendritic protrusions
shorter than 1 μm with clearly visible head and neck were
counted as spines, and dendritic protrusions longer than 1
μm and devoid of head and neck were counted as filo-
podia. For analysis of synaptic contacts, four secondary
dendrites were randomly chosen per neuron and signals
positive for either VGLUT1 (excitatory contacts) or VGAT
(inhibitory contacts) were manually counted among ap-
proximately 50-μm-long segments per dendrite.
Statistical analysis
For all analyses in primary culture, five to eight neurons
from three independent experiments were analyzed per
condition; ‘n’ therefore ranged between 15 and 22.
GraphPad Prism 5.01 (GraphPad Software, La Jolla, CA,
USA) was used for all statistical analyses. Depending on the
datasets, analysis was performed with unpaired Student’s t-
test or one-way ANOVA with Bonferroni post hoc test if
data were normally distributed or with the Mann-Whitney
U test or the Kruskal-Wallis test with Dunn’s multiple com-
parison post hoc test if data were not normally distributed.
Results
Clinical phenotype
Participant 1 (P1) (c.1527G > A) is a 5-year-old male that
we have previously described [17] whose parents first
became concerned about his development due to social
and language delays. Prior to identifying a SHANK3 muta-
tion using whole exome sequencing, a 17q12 microduplica-
tion had been detected and previously described [36]. As
such, caution is warranted in making direct phenotypic
comparisons across the mutations described here and else-
where. P1 has the use of approximately 5 to 10 words to
identify objects when prompted, but he does not have any
communicative language. While he is able to initiate inter-
actions and make eye contact at times, he does not engage
in reciprocal social interaction and is not interested in otherchildren. Behaviorally, he shows significant repetitive behav-
ior, including forced expirations, pacing, and opening and
closing doors. He tends to play in a patterned way and
has pronounced deficits in imitation, pretend play, and
symbolic play. There is also significant difficulty sus-
taining focus, and he can be quite hyperactive. P1 met
criteria for autistic disorder on the ADI-R, ADOS-G,
and DSM-IV (Additional file 1: Table S1). With regard
to his adaptive behavior, P1 demonstrates difficulties
among all domains and overall functioning is low. He
requires substantial support with the majority of self-
care tasks, including feeding and dressing, and he is
not toilet trained. He does eat and sleep well, however.
Cognitively, P1 demonstrates abilities ranging from a 6-
month-old (expressive language) to 15-month-old (fine
motor) level on the Mullen, with significant variability
in his profile. He shows relative strengths in fine and
gross motor skills, understands basic instructions, and
expresses himself with vocalizations and some gestures.
He has difficulty labeling most objects and does not follow
two-step instructions. P1 has no chronic medical problems.
He has never had a seizure, and an electroencephalography
(EEG) in the past was within normal limits. A past mag-
netic resonance imaging (MRI) revealed diffuse ventricular
enlargement and thinning of the parieto-occipital white
matter and corpus callosum. P1 has no renal or cardiac ab-
normalities but is reported to be allergic to penicillin. He
has hypotonia and mild nonspecific gait abnormalities with
toe walking. On dysmorphology exam, P1 has long eye-
lashes, protruding ears, broad nasal bridge, full lips, and
macrocephaly. Skin exam revealed two café au lait spots on
his back (Additional file 2: Table S2).
Participant 2 (P2) (c.2497delG) is a 7-year-old male also
previously described by us [17] whose parents first became
concerned about his development at 6 months old due to
hypotonia and significant difficulty eating solid foods. Al-
though he is nonverbal, he developed some adapted sign
language to a maximum of ten adapted signs. His receptive
language abilities (age equivalent: 13 months) are stronger
than his expressive abilities (age equivalent: 5 months), but
he does not follow simple directions (see below). P2 is able
to make eye contact and engage with others, and when
interested, he will smile and wave. He will repetitively put
nonfood objects in his mouth and is also described as being
obsessed with electronics and phones, while there are no
other compulsive or ritualistic behaviors. Sensory symp-
toms include a high pain threshold, and he does not like to
wear shoes or socks. He also has poor thermoregulation
and gets cold very easily. On autism-focused diagnostic
instruments, P2 met criteria on all three ADI-R domains
(social, communication, and repetitive behaviors), but not
on the ADOS-G or the DSM-IV, and overall, he did not
meet overall consensus criteria for an autism spectrum dis-
order (Additional file 1: Table S1). In terms of associated
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to focus for more than 45 to 60 s at a time. He is extremely
active and restless and has the potential to be aggressive.
Sleeping difficulties are prominent and characterized by
early morning wakening. His adaptive functioning is low
overall; P2 is unable to dress or feed himself, and he is not
toilet trained. His gait is apraxic with left foot dragging and
pronation of his feet bilaterally. However, he is able to ride
a tricycle and to climb stairs with alternating feet. Cognitive
testing shows that P2 is functioning at a 5-month-old
(expressive language) to 20-month-old (gross motor)
level on the Mullen. He is able to understand some
simple commands and questions, in addition to identify
common objects. However, he is not able to follow direc-
tions or label body parts. In terms of medical features, P2
has been diagnosed with a seizure disorder and has local-
ized sleep-potentiated epileptiform discharges mainly in
the midline and central regions during slow wave sleep.
There has never been a seizure observed on EEG, al-
though clinically, they are accompanied by myoclonic
twitching of his ankle and face. A previous MRI study
showed evidence of leukodystrophy but was otherwise
within normal limits. There was evidence of a significant
regression in sign language and motor skills around 6
years old in the context of an increase of seizure activity.
At one point during that period, P2 stopped walking for
about 6 weeks and then slowly regained his ambulatory
skills as the seizures were better controlled. A full meta-
bolic disease workup was negative, but P2 has a short stat-
ure, and a feeding tube is in place. He has gastrointestinal
symptoms manifested by periods of fluctuating diarrhea
and constipation and severe gastroesophageal reflux dis-
ease (GERD) treated with famotidine. He has a history of
recurring ear infections requiring myringotomy tube
placement at 2 years old. He has no renal or cardiac prob-
lems, and no allergies to food or medications. In terms of
dysmorphic physical features, P2 has short stature and
mild dolicocephaly (Additional file 2: Table S2).
Participant 3 (P3) (c.5008A > T) is a 12-year-old male
whose parents first became concerned about his develop-
ment at 2 ½ years old due to language regression and feed-
ing problems. He had developed approximately 10 to 15
words by 18 months but subsequently lost all expressive
languages. His language comprehension is also limited,
but he is reportedly able to understand approximately 40
signs. He can express his needs through a Picture Ex-
change Communication System (PECS), but not consist-
ently. P3 interacts with family members but is generally
uninterested in social interaction. He exhibits significant
repetitive behaviors and will watch the same portion of a
television show or movie repeatedly. He also engages in
motor stereotypies, including hand flapping and rocking.
He may grind his teeth, chew compulsively, and make re-
peated stereotypic vocalizations. He is also sensory seekingthrough tactile modalities, including pressure, and has a
high pain threshold. P3 met full criteria for autistic dis-
order on the ADI-R, ADOS-G, and DSM-IV (Additional
file 1: Table S1). In terms of associated features, he may
become aggressive and rarely bites others but is not self-
injurious. There is no motoric hyperactivity, but he has
significant sleep difficulties, including delays in sleep onset
and early morning awakening. His adaptive functioning is
low in all domains. He continues to have difficulty eating
solid food and is unable to manipulate utensils. He has
hypotonia but is able to ride a tricycle. P3 is not toilet
trained. Cognitive functioning is also low in the 8-month
(receptive language) to 30-month (gross motor) range on
the Mullen. P3 was diagnosed with epilepsy at 7 years old
after a 48-h video EEG showed clinical events but without
electrographic correlation. A subsequent MRI that year
revealed a venous angioma. During the same period of
time, P3 experienced a regression in motor skills where
he previously was able to hold a pencil and write his
name but then lost this skill. At 8 years old, he experienced
a 9-month period of significant muscle weakness and was
unable to ambulate for 6 months. He continues to have
hypotonia with mild nonspecific gait abnormalities, includ-
ing intoeing. He has no renal and no cardiac abnormalities.
P3 is reportedly allergic to casein and gluten and on a re-
stricted diet. He also has a history of chronic diarrhea
(seven to eight times a day) and recurring ear infections,
which have both improved. In terms of dysmorphic fea-
tures, P3 is noted to have deep set eyes, fifth finger clino-
dactyly, and second toes overlapping (Additional file 2:
Table S2).
Domain composition and biochemical expression analysis
of SHANK3 variants
The full length human SHANK3a protein contains N-
terminal ankyrin repeats (Ank) followed by a Src-homology
3 domain (SH3), a postsynaptic density (PSD)-95/Dlg1/
ZO1 domain (PDZ), a proline-rich region (Pro), Homer
and cortactin binding sites (H +C) and a C-terminal sterile
alpha motif (SAM) domain (Figure 1A). In the aforemen-
tioned individuals, the c.1527G >A nonsense mutation
affects exon 12 of SHANK3 resulting in a truncation within
the SH3 domain, the c.2497delG frameshift mutation
in exon 21 disrupts the proline-rich region, and the
c.5008A > T nonsense mutation in exon 22 disrupts
the SAM domain. The corresponding fusion proteins,
named SHANK3, G1527A, 2497delG, and A5008T in
this study, have been engineered to harbor an N-terminal
GFP-tag followed by a Myc-tag. Both G1527A and
2497delG are predicted to lack the SHANK3 C-terminus
including the proline-rich region, Homer and cortactin
binding sites and the C-terminal SAM domain (and the
PDZ domain and parts of the SH3 domain in case of
G1527A), while A5008T is only predicted to lack most of
Figure 1 Domain composition and expression analysis of SHANK3 variants. (A) Schematic overview of the SHANK3 constructs/fusion proteins
used for overexpression experiments in this study. All constructs harbor an N-terminal GFP tag followed by a Myc-tag (indicated in green and orange,
respectively). Domains are marked as it follows: Ank, ankyrin repeat domain; SH3, Src homology 3 domain; PDZ, postsynaptic density 95/discs
large/zonula occludens-1 domain; Pro, proline-rich region; H, Homer binding site; C, cortactin binding site; and SAM, sterile alpha motif domain.
SHANK3 is based on the full-length human SHANK3a sequence containing all of these domains. The truncated SHANK3 variants are identified as
G1527A, 2497delG, and A5008T, and each is based on the SHANK3a sequence harboring either c.1527G > A, c.2497delG, or c.5008A > T, respectively.
Predicted premature stop sites are marked by STOP in red. (B) Functional validation of the SHANK3 constructs in HEK293T cells via detection of the
overexpressed fusion proteins SHANK3, G1527A, 2497delG, and A5008T by Western blot analysis using either anti-GFP (left panel) or anti-Myc (right
panel) antibodies. kDa, kilodalton.
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of our expression constructs, we transfected HEK293T
cells and detected the corresponding fusion proteins by
Western blot analysis of whole cell extracts using
either anti-GFP (Figure 1B, left panel; Additional file 3:
Figure S1A), anti-Myc (Figure 1B, right panel), or polyclonal
anti-Shank3 antibodies (Additional file 3: Figure S1B,C).
All four antibodies detected wild-type SHANK3 at the
correct size (predicted molecular weight including tags ap-
proximately 220 kD). Both anti-GFP and anti-Myc anti-
bodies also detected all three truncated fusion proteins
G1527A (approximately 90 kD), 2497delG (approximately
130 kD), and A5008T (approximately 215 kD) at the cor-
rect size (Figure 1B). The anti-Shank3 PRC antibody recog-
nized 2497delG and A5008T but failed to detect G1527A
due to the lack of antigen sequence within this fusion pro-
tein (Additional file 3: Figure S1B, for antigen sequence, see
[31]). We therefore used a novel anti-Shank3 N-term anti-
body, which successfully detected G1527A (Additional
file 3: Figure S1C).
Nuclear accumulation of truncated SHANK3 variants
G1527A and 2497delG
We transfected rat primary hippocampal neurons at
DIV11 and analyzed subcellular localization of SHANK3,
G1527A, 2497delG, and A5008T at DIV14. The den-
dritic tree and dendritic spines were visualized by co-
transfection of DenMark [30], with empty vector used as
Control (Figure 2A,B,C,D,E). SHANK3 localized to the
somatodendritic compartment where it mainly formed
cluster-like structures within dendrites, spines, and at excita-
tory synapses (Figure 2B, Additional file 4: Figure S2A,B) -
as previously shown for its homologues in mouse and rat[23,26,37,38]. A5008T also localized to the somatodendri-
tic compartment and appeared in cluster-like structures
within dendrites and at excitatory synapses - albeit to a
much lesser extent than SHANK3 (Figure 2E, Additional
file 4: Figure S2A,B). In contrast, G1527A and 2497delG
exclusively co-localized with DAPI-positive nuclei in
transfected neurons, thus implicating nuclear or peri-
nuclear enrichment of both fusion proteins (Figure 2C,D).
To further investigate this phenomenon, overexpres-
sion experiments were performed in HEK293T cells,
which better allows biochemical detection of the fusion
proteins in subcellular fractions due to higher transfec-
tion rates. In line with our observations in primary
neuronal cultures, both G1527A and 2497delG exclu-
sively co-localized with DAPI-positive nuclei and were
found biochemically enriched within the nuclear frac-
tion (Additional file 5: Figure S3A,B).Overexpression of truncated SHANK3 variants results in
distinct alterations of dendritic tree complexity
To assess neuronal morphology of transfected neurons, we
first analyzed the dendritic tree. Primary dendrite number
revealed no differences among all conditions (Additional
file 6: Figure S4). Subsequent Sholl analysis showed that
dendritic tree complexity was identical in Control and with
overexpressed SHANK3 (Figure 3A). However, overexpres-
sion of either G1527A or 2497delG resulted in a much
lower complexity of the dendritic tree when compared to
either Control or SHANK3 (Figure 3B,C) indicating
severely impaired dendritic branching. Interestingly,
overexpression of A5008T did not show any gross alter-
ations of dendritic arborization when compared to
Figure 2 Nuclear accumulation of truncated SHANK3 variants G1527A and 2497delG. (A-E) Subcellular distribution of empty vector-based GFP
(Control) (A), full-length GFP-Myc-SHANK3 (SHANK3) (B), or the truncated GFP-Myc-SHANK3 variants G1527A (C), 2497delG (D), and A5008T (E),
after transient overexpression (DIV11-14) in rat primary hippocampal neurons. All neurons shown were co-transfected with the DenMark construct
[30] containing an mCherry sequence to demarcate dendrites and spines in red. They were further immunostained for VGLUT1 (not shown), and
nuclei were visualized by DAPI. In each panel (A-E), one representative co-transfected neuron is depicted. The picture on the left is a merge of
the GFP and DenMark signals, while the picture in the middle shows only the GFP signal. The upper insets on the right show a merge of GFP
and DAPI signals or the DAPI signal alone, and the lower inset on the right shows a representative secondary dendrite as a merge of the GFP
and DenMark signals. Note the strong overlap of both G1527A and 2497delG with the DAPI signal.
Cochoy et al. Molecular Autism  (2015) 6:23 Page 7 of 13Control, but some enhanced branching of distal dendrites
when compared to SHANK3 (Figure 3D).
Overexpression of truncated SHANK3 variants results in
distinct alterations of dendritic spines and synaptic
contacts
Further assessment of neuronal morphology included
the evaluation of spines and filopodia among secondarydendrites of transfected neurons (Figure 4A,B,C). Over-
expression of either G1527A or 2497delG resulted in a
strong reduction in spine density when compared to either
Control or SHANK3 (Figure 4B), while filopodia density
remained unchanged (Figure 4C). In contrast, A5008T
overexpression did not affect spine or filopodia density at
all (Figure 4B,C). These data show that overexpression of
either G1527A or 2497delG results in a specific loss of
Figure 3 Overexpression of truncated SHANK3 variants results in distinct alterations of dendritic tree complexity. (A-D) Dendritic tree complexity
of rat primary hippocampal neurons co-transfected with DenMark and either empty vector-based GFP (Control), full-length GFP-Myc-SHANK3
(SHANK3), or the truncated GFP-Myc-SHANK3 variants G1527A, 2497delG, and A5008T (DIV11-14). (A) Representative images of the DenMark signal
in rat primary hippocampal neurons overexpressing either Control or SHANK3, as indicated. The panel on the right shows a Sholl analysis of
Control (white-filled circles) vs. SHANK3 (black-filled circles). (B-D) Representative images of the DenMark signal in rat primary hippocampal
neurons overexpressing either G1527A (B), 2497delG (C), or A5008T (D), as indicated. The panels below each image show Sholl analyses either
of Control (white-filled circles, upper panel) or SHANK3 (black-filled circles, lower panel) vs. the corresponding truncated SHANK3 variant (red-filled
circles for G1527A in (B), green-filled circles for 2497delG in (C), and blue-filled circles for A5008T in (D)). *P < 0.05, **P < 0.01, ***P < 0.001 compared
with either Control or SHANK3.
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filopodia per μm dendrite (Figure 4B,C, for spine/filopodia
and filopodia/spine ratios, see Table 1), while there was no
significant effect of A5008T overexpression on spine orfilopodia density (Figure 4B,C, for spine/filopodia and filo-
podia/spine ratios, see Table 1).
We next analyzed presynaptic specializations among sec-
ondary dendrites of transfected neurons and discriminated
Figure 4 Overexpression of truncated SHANK3 variants results in distinct alterations of dendritic spines and synaptic contacts. Evaluation of
dendritic spines (A-C) and synaptic contacts (D-F) in rat primary hippocampal neurons co-transfected with DenMark and either empty vector-
based GFP (Control), full-length GFP-Myc-SHANK3 (SHANK3), or truncated GFP-Myc-SHANK3 variants (G1527A, 2497delG, A5008T) (DIV11-14). (A)
Representative images of the DenMark signal in secondary dendrites of rat primary hippocampal neurons overexpressing either Control, SHANK3,
G1527A, 2497delG, or A5008T as indicated. (B) Quantitative analysis of spine density. (C) Quantitative analysis of filopodia density. (D) Representative
images of VGLUT1-positive (upper two rows) and VGAT-positive (lower two rows) presynaptic specializations among secondary dendrites of rat primary
hippocampal neurons overexpressing either Control, SHANK3, G1527A, 2497delG, or A5008T, as indicated. (E) Quantitative analysis of VGLUT1-positive
puncta density. (F) Quantitative analysis of VGAT-positive puncta density. White bars, Control; black bars, SHANK3; red bars, G1527A; green bars,
2497delG; and blue bars, A5008T. *P < 0.05 and ***P < 0.001 compared with Control; ooP < 0.01 and oooP < 0.001 compared with SHANK3.
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Table 1 Spine/filopodia and filopodia/spine ratios of rat
primary hippocampal neurons overexpressing different
SHANK3 variants






Cochoy et al. Molecular Autism  (2015) 6:23 Page 10 of 13excitatory and inhibitory contacts by immunostaining for
either VGLUT1 or VGAT (Figure 4D,E,F). In line with our
findings on spines, the dendritic contact sites for excitatory
synapses, overexpression of either G1527A or 2497delG, re-
sulted in a major loss of VGLUT1-positive puncta per μm
dendrite, while VGAT puncta density remained unaffected
(Figure 4D,E,F). In contrast, there was no detectable change
in the density of either VGLUT1- or VGAT-positive puncta
when A5008T was compared to either Control or SHANK3
(Figure 4D,E,F). These findings demonstrate that overex-
pression of both G1527A and 2497delG leads to a specific
decrease in excitatory, but not inhibitory contacts, thus
likely shifting the excitation/inhibition (E/I) balance to-
wards inhibition. In contrast, no E/I imbalance phenotype
can be implicated at this point when examining overexpres-
sion of A5008T in primary hippocampal culture.
Discussion
In this study, we have described, for the first time, a
novel truncating stop mutation in an individual with the
diagnosis of both ASD and ID (c.5008A > T) (Table 2).
In addition, in vitro analyses with this and two other re-
cently identified truncating stop mutations (c.1527G > A
and c.2497delG, [17]) addressed the question if distinct
mutations in SHANK3 result in mutation-specific or
converging morphological phenotypes.
Interestingly, we found that SHANK3a variants harbor-
ing either c.1527G >A or c.2497delG, thus lacking large
but distinct parts of the protein’s C-terminus (Figure 1A),
exhibit overlapping phenotypes in all morphological pa-
rameters investigated. When overexpressed, both trun-
cated proteins exclusively accumulate in the nuclear
compartment of transfected cells (Figures 2C,D, Additional
file 5: Figure S3A,B) and this is accompanied by a severe
reduction of dendritic tree complexity (Figure 3A,B,C).
Moreover, we found a specific reduction of dendriticTable 2 Genetic information on the three participants include
Sex Diagnosis Rearrangement A
P1 M ASD/ID c.1527G > A p
P2 M ID c.2497delG p
P3 M ASD/ID c.5008A > T pspine and excitatory, but not inhibitory synapse density
(Figure 4A,B,C,D,E,F). These findings are in line with
previous in vitro studies showing similar phenotypes
for rodent homologue Shank3a variants harboring ei-
ther c.3679_3680insG or c.3349C > T [23,25].
In contrast, none of these phenotypes was observed in
neurons overexpressing SHANK3a haboring the c.5008A >
T mutation. However, some minor alterations in neuronal
morphology were detected, and interestingly, they were op-
posite from the ones related to c.1527G >A and c.2497delG
as c.5008A >T produced slightly enhanced complexity of
the distal dendritic tree (Figure 3D).
With respect to subcellular localization of truncated
SHANK3, an important aspect to consider is domain
composition. The SHANK3a c.5008A > T variant is only
lacking a small part of the protein’s C-terminus, thereby
exclusively disrupting the SAM domain (Figure 1A), a
domain needed for the correct assembly of Shanks in
the PSD [27]. In line with this, it still localizes to den-
drites and excitatory synapses of transfected neurons in
cluster-like structures, although with a much lower effi-
ciency as compared to full-length SHANK3a (Figure 2E,
Additional file 4: Figure S2A,B). The two other truncated
SHANK3a variants analyzed here are lacking major parts
of the C-terminus including distinct stretches of the
proline-rich domain and - in all cases - the Homer binding
site (a dendritic localization signal), a synaptic targeting
element in between the Homer and cortactin binding sites
and the SAM domain (Figure 1A). In line with this, each
of these variants never forms cluster-like structures within
dendrites or at spine synapses, but rather localizes to the
nucleus of transfected neurons (Figure 2C,D).
A recent study on the transcriptional and functional
complexity of the rodent Shank3 gene convincingly
delineates all rodent Shank3 isoforms (Shank3a-f ) and
reports distinct and/or overlapping phenotypes for each
isoform with respect to subcellular distribution and
neuronal morphology after overexpression in primary
hippocampal neurons [37]. Summarizing what was ob-
served, selected Shank3 isoforms either increase the
number of spines and excitatory synapses or show the
opposite effect, likely depending on their domain com-
position and subcellular localization. Intriguingly, the
Shank3 isoform Shank3b, which only contains the anky-
rin repeats, the SH3 domain, and the PDZ domain [37],
resembles two of the shorter truncated SHANK3a vari-
ants described here. In primary hippocampal neurons,d into this study
a change Inheritance Reference
.W509X De novo Soorya et al. 2013 [17]
.P834RfsX58 De novo Soorya et al. 2013 [17]
.K1670X Not from mother This study
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panied by a reduced number of mature spines and exci-
tatory synapses [37] - just as we report in this study for
overexpression of SHANK3a harboring either c.1527G >A
or c.2497delG mutations (Figures 2, 4) and as others have
reported in previous studies for the rodent Shank3a
homologue harboring either c.3679_3680insG or c.3349C >
T [23,25].
Although the exact function of each isoform is yet to be
determined, it can already be hypothesized at this point
that in a healthy neuron, the expression of SHANK3 iso-
forms is fluid, adapting to the ever-changing needs of the
cell. Hence, we can speculate that in neurons from indi-
viduals with heterozygous stop mutation in SHANK3,
there will be disrupted functionality under specific condi-
tions, due to expression of variant proteins at key stages.
Genotype-phenotype correlations can be complicated
because of the potential for additional genetic variation
contributing to more or less severe phenotypes. In fact,
P1 has both an early truncating mutation in SHANK3, as
well as a 17q duplication, and has one of the more
severe presentations observed at the Seaver Autism Center.
However, it is still of interest to note that the three individ-
uals described here are all significantly affected, irrespective
of the extent of the truncation. In fact, it is of particular
interest that the A5008T variation is associated with a
very mild cellular phenotype but with a severe behavioral
phenotype in the participant. A better understanding of
this association will require additional studies as noted
below, although it is also possible that A5008T causes a
different cellular phenotype, which has not been assessed
in this study.
Transfection experiments as we have carried out here
involve the modification of a single SHANK3 isoform
(SHANK3a). In addition, we cannot assess other genetic
variation that may alter severity and we cannot exclude
the possibility that in patient cells, both c.1527G > A and
c.2497delG - as being located in coding exons upstream
the natural stop codon - lead to SHANK3 haploinsuffi-
ciency due to degradation of the truncated proteins by
the nonsense-mediated mRNA decay machinery [39]. It
will therefore be essential to differentiate neurons from
induced pluripotent stem cells (iPSCs) of participants af-
fected by any of the aforementioned stop mutations and
analyze neuronal morphology as well as domain com-
position, subcellular localization, and mRNA and protein
expression of endogenous SHANK3. However, neuronal
culture will never completely reflect the impact of a
given mutation on the network level in vivo. Hence, an-
other essential approach to study mutations in SHANK3
would be to generate animal models that carry the human
mutation. With respect to stop mutations disrupting exon
21 of SHANK3, such as c.2497delG from this study, the
recently published Shank3ΔC/ΔC mouse, which is an exon21 deletion model [40], may already provide some insights.
Importantly, increases in C-terminally truncated Shank3
variants are detectable in hippocampal lysates from these
animals. Compared to other Shank mutant mice [41,42],
only minimal social deficits were observed in these ani-
mals, and increased repetitive behavior was only evi-
dent at a certain age (10 to 13 months). CA1 pyramidal
neurons did not exhibit a morphological phenotype.
The Shank3ΔC/ΔC mutants did clearly show impaired
spatial learning and corresponding abnormalities in
hippocampal CA3-CA1 physiology though, including
decreased long-term potentiation (LTP) and decreased
NDMA receptor-mediated synaptic transmission. How-
ever, it has to be noted that only analyses of homozygous
mutants have been reported so far. Studying heterozygous
mutants - as the more ‘human-like’ model - would pos-
sibly reveal different phenotypes not only in this but also
in other models mimicking human mutations in SHANK3.
Conclusions
Our in vitro overexpression data show that the location
of a stop mutation within the SHANK3a sequence de-
termines both subcellular localization of the truncated
protein and the morphological phenotype of the trans-
fected neuron.
Considering domain composition of SHANK3, our data
support previous studies [15,23-29,37] and strengthen the
fact that only SHANK3 variants with an intact C-terminus
including the Homer binding site, a synaptic targeting
element in between the Homer and cortactin binding sites
and the SAM domain, correctly and efficiently localize to
synapses. Any disruption of these domains results in a dis-
tinct phenotype of dendritic and synaptic morphology.
Interestingly, our data imply that loss of the Homer and
cortactin binding sites is sufficient to induce nuclear accu-
mulation of the corresponding SHANK3 variants. This
again supports previous studies proposing that SHANK3
might not only serve as a synaptic but also serve as a nu-
clear protein [25,37] - although its exact nuclear function
still remains an enigma.
Considering recent findings on the complexity of both
subcellular localization and distinct morphological impact
of different rodent Shank3 isoforms in healthy neurons
[37], we propose that any heterozygous deleterious mu-
tation in SHANK3 will lead to altered SHANK3 isoform
expression and thereby result in distinct spatial and
temporal perturbations of SHANK3-dependent cellular
processes. Although we cannot further investigate such
a proposed patho-mechanistic model in the in vitro
assay used in this study, its effect on the network level
within the complex and dynamic architecture of the
brain would be predicted to be substantial. Moreover, it
would also be consistent with our observation that the
clinical phenotype remains quite severe in all three
Cochoy et al. Molecular Autism  (2015) 6:23 Page 12 of 13individuals included in this study, with clear overlap in
the symptom presentation, regardless of whether most
or only part of SHANK3 is missing.Additional files
Additional file 1: Table S1. Descriptive and diagnostic data by
participant: Mullen Scales of Early Learning, Nonverbal IQ estimate,
Vineland Adaptive Behavior Scales, ADI-R, and ADOS-2.
Additional file 2: Table S2. Medical features (a) and dysmorphic
features (b) of the three participants.
Additional file 3: Figure S1. Additional biochemical expression analysis
of SHANK3 variants in HEK293T cells. The anti-GFP antibody detects GFP
at the right size after overexpression of the empty vector in HEK293T cells
(A). Only the fusion proteins SHANK3, 2497delG and A5008T, but not
G1527A, can be biochemically detected by the self-made anti-Shank3
PRC antibody (B). Successful detection of G1527A (as well as rat Shank3a,
SHANK3, and 2497delG) was accomplished with a novel self-made
anti-Shank3 N-term antibody (C). kDa, kilodalton.
Additional file 4: Figure S2. Additional subcellular distribution analysis
of SHANK3 variants in rat primary hippocampal neurons. Quantitative
analysis of GFP cluster density (A) and the density of GFP clusters
overlapping with VGLUT1 signals (B) among secondary dendrites of rat
primary hippocampal neurons filled with DenMark and overexpressing
either SHANK3 (black bars) or A5008A > T (blue bars) as indicated
(DIV11-14). ***P < 0.001 compared with SHANK3.
Additional file 5: Figure S3. Nuclear accumulation of the SHANK3
variants G1527A and 2497delG in HEK293T cells. (A, B) Subcellular
distribution of SHANK3, G1527A, 2497delG and A5008T in HEK293T cells.
(A) Merged pictures of the GFP signal, the phalloidin signal (visualizing
the actin cytoskeleton) and the DAPI signal (upper row), the GFP signal
alone (middle row) and the DAPI signal alone (lower row). Note strong
overlap of both G1527A and 2497delG with the DAPI signal. (B)
Biochemical detection of overexpressed G1527A and 2497delG in
cytosolic (Cyt) and nuclear (Nuc) fractions isolated from HEK293T cells
using an anti-GFP antibody. Anti-GAPDH and anti-Histone H3 anti-
bodies were used to control fractionation as indicated. kDa, kilodalton.
Additional file 6: Figure S4. Primary dendrite number of rat primary
hippocampal neurons overexpressing SHANK3 variants. Quantitative
analysis of the number of primary dendrites of rat primary hippocampal
neurons filled with DenMark and overexpressing either Control (white
bar), SHANK3 (black bar), G1527A (red bar), 2497delG (green bar), or
A5008A > T (blue bar) as indicated (DIV11-14). No statistical differences
were observed.Abbreviations
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